Innodem Neurosciences
Innodem Neurosciences is a Montreal-based digital health and AI company specializing in the development of innovative eye-tracking technology for neurological assessment. Their mission is to provide easier remote testing for neurodegenerative diseases and mental disorders, improving diagnosis, monitoring, and patient outcomes through scalable, non-invasive, and AI-powered solutions.
Industries
Nr. of Employees
small (1-50)
Innodem Neurosciences
Patents
Method and a system for detection of eye gaze-pattern abnormalities and related neurological diseases
US-12396641-B2
View DetailsMethod and a system for detection of eye gaze-pattern abnormalities and related neurological diseases
US-11503998-B1
View Details
Method and a system for detection of eye gaze-pattern abnormalities and related neurological diseases
US-12396641-B2
View DetailsMethod and a system for detection of eye gaze-pattern abnormalities and related neurological diseases
US-11503998-B1
View DetailsProducts
Tablet-based eye-tracking application for neurological assessment
A mobile application that converts a consumer tablet into a medical assessment tool by recording eye movements during short visual tasks, extracting oculomotor metrics, and producing automated analytics including estimated clinical scores for neurological conditions.
Tablet-based eye-tracking application for neurological assessment
A mobile application that converts a consumer tablet into a medical assessment tool by recording eye movements during short visual tasks, extracting oculomotor metrics, and producing automated analytics including estimated clinical scores for neurological conditions.
Services
Design and operational support for observational and longitudinal studies to collect eye-tracking, cognitive, and disease-severity metrics in neurodegenerative and cancer-related cognitive impairment cohorts.
Training, validation, and deployment of machine learning models that classify disease status and estimate clinical scores from oculomotor metrics.
Deployment of a remote self-testing platform enabling patients to perform short visual tasks at home on tablets with secure transmission of results to clinicians and study teams.
Design and operational support for observational and longitudinal studies to collect eye-tracking, cognitive, and disease-severity metrics in neurodegenerative and cancer-related cognitive impairment cohorts.
Training, validation, and deployment of machine learning models that classify disease status and estimate clinical scores from oculomotor metrics.
Deployment of a remote self-testing platform enabling patients to perform short visual tasks at home on tablets with secure transmission of results to clinicians and study teams.
Expertise Areas
- Digital biomarker development
- Eye movement and gaze analytics
- Clinical trial design and execution (observational, longitudinal)
- Software-as-a-medical-device (SaMD) development
Key Technologies
- Tablet-embedded camera eye tracking
- Eye movement biomarker extraction
- Gaze mapping analytics
- Machine learning classifiers
News & Updates
Innodem Neurosciences receives 6 million US Dollars of financing from Morningside Group
Innodem secured Series A funding to support development and commercialization of its digital biomarkers for neurodegenerative diseases.
Innodem signs strategic partnership with Novartis Pharmaceuticals Canada
A multi-year collaboration to develop and validate eye-tracking technology for MS disease monitoring.
Innodem's ETNA™-MS obtains Health Canada's approval
The software is cleared for clinical use to assess MS disease progression.
Innodem publishes study in Nature on tablet-based eye-tracking technology
Demonstrates the potential of mobile eye-tracking to distinguish Parkinson's Disease and assess cognitive abilities.
Dr. Paul Giacomini joins Innodem as Chief Medical Officer
A leading neurologist specializing in neuroinflammatory disorders and neuroimaging.
Patent Patents in North America, Europe, Japan, China
Patented technology for eye-tracking biomarkers and software.
Innodem Neurosciences receives 6 million US Dollars of financing from Morningside Group
Innodem secured Series A funding to support development and commercialization of its digital biomarkers for neurodegenerative diseases.
Innodem signs strategic partnership with Novartis Pharmaceuticals Canada
A multi-year collaboration to develop and validate eye-tracking technology for MS disease monitoring.
Innodem's ETNA™-MS obtains Health Canada's approval
The software is cleared for clinical use to assess MS disease progression.
Innodem publishes study in Nature on tablet-based eye-tracking technology
Demonstrates the potential of mobile eye-tracking to distinguish Parkinson's Disease and assess cognitive abilities.
Dr. Paul Giacomini joins Innodem as Chief Medical Officer
A leading neurologist specializing in neuroinflammatory disorders and neuroimaging.
Patent Patents in North America, Europe, Japan, China
Patented technology for eye-tracking biomarkers and software.